KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $3.6 billion.

  • Vertex Pharmaceuticals' Accumulated Expenses rose 1223.1% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 1223.1%. This contributed to the annual value of $2.8 billion for FY2024, which is 502.01% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Accumulated Expenses of $3.6 billion as of Q3 2025, which was up 1223.1% from $3.3 billion recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Accumulated Expenses peaked at $3.6 billion during Q3 2025, and registered a low of $1.5 billion during Q2 2021.
  • Its 5-year average for Accumulated Expenses is $2.5 billion, with a median of $2.6 billion in 2023.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Accumulated Expenses plummeted by 696.76% in 2021, and later soared by 4296.26% in 2022.
  • Vertex Pharmaceuticals' Accumulated Expenses (Quarter) stood at $1.7 billion in 2021, then increased by 26.69% to $2.1 billion in 2022, then rose by 24.86% to $2.7 billion in 2023, then grew by 5.02% to $2.8 billion in 2024, then grew by 29.58% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q3 2025, $3.3 billion for Q2 2025, and $3.0 billion during Q1 2025.